Sharief Taraman, Cognoa Inc.’s chief medical officer, has high hopes for using artificial intelligence and machine learning (AI/ML) to change the world of pediatric medicine. But he’s also wary that many of the disparities in the health care system today may become amplified in the medical software of tomorrow if developers are not careful.
In June the US Food and Drug Administration authorized Cognoa’s de novo for the Canvas Dx to help diagnose autism in children. The software as a medical device (SaMD) was...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?